Literature DB >> 16103747

Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model.

A Hegele1, A Dalpke, K Heeg, P Barth, Z Varga, R Hofmann, P Olbert.   

Abstract

Bacillus Calmette-Guérin is established in the prophylaxis of recurrent intermediate and high-risk superficial bladder cancer and induces an unspecific, Th1-biased local immune response. Small CpG oligonucleotides (CpG ODN) containing a central unmethylated CpG motif are able to mimic the immunostimulatory activity of bacterial DNA. The purpose of the present study was to evaluate the antineoplastic properties of intravesically administered CpG ODN in an orthotopic murine bladder cancer model. MB49 tumor cell suspension was instilled transurethrally in female C57/BL6 mice on day 0. Mice were divided in three groups of 12 animals. Four mice in each group received either stimulative CpG ODN, non-stimulative GpC ODN or PBS intravesically: group I on day 3, group II on day 5, group III on day 7. After sacrifice 7 days after treatment, bladders were removed and histological examinations were performed. Single instillation of CpG ODN revealed antineoplastic effects in every group demonstrated by significantly lower bladder weight compared with non-stimulative GpC ODN- and PBS-treated mice. Histological examination showed extensive infiltration of macrophages and lymphocytes in CpG ODN-treated mice, whereas PBS- and GpC ODN-treated mice showed solid tumor growth with only few leucocytes. Intravesically applied immunostimulative DNA demonstrated antitumoral activity in an orthotopic murine bladder cancer model. A single instillation seems to be sufficient to reduce tumor load. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103747     DOI: 10.1159/000087380

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.

Authors:  Tomoko Hayashi; Brian Crain; Maripat Corr; Michael Chan; Howard B Cottam; Roberto Maj; Alcide Barberis; Lorenzo Leoni; Dennis A Carson
Journal:  Int J Urol       Date:  2010-03-11       Impact factor: 3.369

2.  [Research in urologic university clinics. Assessment of current status and perspectives].

Authors:  K Miller; H Krause
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

3.  [Focus on tumor immunology of transitional cell carcinoma].

Authors:  P J Olbert; A J Schrader; A Hegele; R Hofmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo.

Authors:  Sven Klaschik; Debra Tross; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2009-01-29       Impact factor: 4.962

5.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

6.  [Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression].

Authors:  P J Olbert; A J Schrader; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 7.  Toll-like receptors in urothelial cells--targets for cancer immunotherapy.

Authors:  Hélène LaRue; Cherifa Ayari; Alain Bergeron; Yves Fradet
Journal:  Nat Rev Urol       Date:  2013-08-27       Impact factor: 14.432

Review 8.  Modulating Immune Response with Nucleic Acid Nanoparticles.

Authors:  Jake K Durbin; Daniel K Miller; Julia Niekamp; Emil F Khisamutdinov
Journal:  Molecules       Date:  2019-10-17       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.